We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$664M
AUM Growth
+$96.5M
Cap. Flow
+$35.6M
Cap. Flow %
5.35%
Top 10 Hldgs %
45.17%
Holding
73
New
23
Increased
14
Reduced
10
Closed
23

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$37.5M
2
AGN
Allergan plc
AGN
+$36.2M
3
STJ
St Jude Medical
STJ
+$33.9M
4
GILD icon
Gilead Sciences
GILD
+$31.7M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$27.4M

Top Sells

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$38.8M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$34.2M
3
CAH icon
Cardinal Health
CAH
+$27.6M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$19.2M
5
CELG
Celgene Corp
CELG
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.5%
2 Miscellaneous 17.62%
3 Consumer Staples 1.19%
4 Technology 0.69%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$39.1M 5.89%
+271,500
New +$36.2M
AMGN icon
2
Amgen
AMGN
$234B
$38.7M 5.83%
+345,700
New +$37.5M
STJ
3
DELISTED
St Jude Medical
STJ
$35.3M 5.32%
+658,000
New +$33.9M
GILD icon
4
Gilead Sciences
GILD
$181B
$33.3M 5.01%
+529,800
New +$31.7M
CBST
5
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$28.8M 4.33%
+452,600
New +$27.4M
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$28.6M 4.31%
471,345
-4,032
-0.8% -$286K
REGN icon
7
Regeneron Pharmaceuticals
REGN
$81.8B
$25.2M 3.79%
80,400
+19,400
+32% +$5.1M
THC icon
8
Tenet Healthcare
THC
$21.5B
$24.3M 3.67%
591,000
+274,800
+87% +$11.5M
CTRX
9
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$23.3M 3.52%
+508,100
New +$26.8M
ARIA
10
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$23.3M 3.5%
1,264,009
-13,100
-1% -$254K
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
$22.8M 3.44%
3,669,593
-1,099,775
-23% -$6.53M
PODD icon
12
Insulet
PODD
$10.1B
$21.7M 3.27%
599,000
+25,700
+4% +$862K
BKD icon
13
Brookdale Senior Living
BKD
$2.8B
$19.9M 3%
757,800
+211,300
+39% +$5.79M
PBYI icon
14
Puma Biotechnology
PBYI
$468M
$18.3M 2.75%
340,165
-199,829
-37% -$10.8M
HCA icon
15
HCA Healthcare
HCA
$90.5B
$17.7M 2.67%
414,400
-318,900
-43% -$12.5M
NUVA
16
DELISTED
NuVasive, Inc.
NUVA
$17M 2.56%
693,392
-70,600
-9% -$1.74M
CELG
17
DELISTED
Celgene Corp
CELG
$15.2M 2.29%
197,200
-204,600
-51% -$14.3M
ZTS icon
18
Zoetis
ZTS
$32B
$14.5M 2.18%
+465,900
New +$14.3M
CMRX
19
DELISTED
Chimerix, Inc.
CMRX
$14.4M 2.16%
653,705
+202,905
+45% +$4.17M
CERS icon
20
Cerus
CERS
$534M
$13.8M 2.07%
2,052,400
-373,000
-15% -$2.03M
HTWR
21
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$13.6M 2.04%
185,125
+22,800
+14% +$1.94M
MRK icon
22
CALL
Merck
MRK
$366B
$13.4M 2.03%
296,060
+34,060
+13% +$1.56M
GMED icon
23
Globus Medical
GMED
$11.1B
$12.9M 1.94%
736,100
+35,400
+5% +$613K
SNDA icon
24
Sonida Senior Living
SNDA
$1.8B
$12.6M 1.9%
39,820
+11,633
+41% +$3.94M
AZN icon
25
AstraZeneca
AZN
$252B
$12.3M 1.85%
+236,100
New +$11.9M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2013 Portfolio in Review

As of Q3 2013, Redmile Group held 73 positions worth $664M, up 17% from $568M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group deployed $35.6M of net new capital in Q3 2013, opening 23 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 345,700 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Celgene Corp, an estimated $14.3M trimmed.

  • Redmile Group's largest Q3 2013 buy was Amgen: 345,700 shares worth $38.7M.
  • Redmile Group added most to Tenet Healthcare in Q3 2013, an estimated $11.5M increase.
  • Redmile Group's biggest Q3 2013 reduction was Celgene Corp, cutting an estimated $14.3M.
  • Redmile Group fully exited Align Technology in Q3 2013, selling an estimated $38.8M.
  • Redmile Group's ten largest holdings make up 45% of its $664M portfolio in Q3 2013.
  • Redmile Group opened 23 new positions and closed 23 in Q3 2013.
  • Redmile Group's portfolio value rose 17% quarter-over-quarter to $664M.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.